| 12.17.21 | Ipsen caps 2021 deal spree with $543M Genfit tie up; Amylyx lines up for Wall Street after FDA U-turn

Laden...

2 jaren geleden

Html
Tekst

This week's sponsor is Aldevron.

Today's Rundown

Ipsen ends 2021 deal spree with $543M biobucks tie-up for Genfit's liver disease drug After FDA U-turn, Amylyx eyes IPO to support ALS drug filings across the world Omega, backer of 150-plus biotechs, lands 7th and largest fund at $650M to build new companies Sponsored: 7 Applications for Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Specimens Pfizer joins $119M round for Novartis-backed cytokines biotech Anaveon to bankroll phase 2 studies Roche's Spark unit blueprints $575M gene therapy manufacturing center in Philly Pfizer's peak COVID sales now pegged at $50B-plus, with vaccine still hauling in $25B by 2027: analysts Precisely targeting liver cancer with logic-gated gene therapy Allergan Aesthetics completes $550M Soliton buy following FTC probe Biogen vows to contest EMA rejection of Aduhelm as EU regulators question weak link to Alzheimer's clinical benefit Oracle in talks to buy Cerner in potential $30B deal: WSJ Fierce Pharma Asia—Merck, Eisai's failed Lenvima trial; J&J, Legend's CAR-T data; AstraZeneca-Samsung COVID pact Chutes & Ladders—Abbott's CEO and president is now also the medtech giant's chairman

Featured Story

Ipsen ends 2021 deal spree with $543M biobucks tie-up for Genfit's liver disease drug

By Annalee Armstrong

After a summer of deals, Ipsen is closing out the year with one last hurrah. The rare-disease-focused biopharma will partner with Genfit on a liver disease drug in a tie-up potentially worth a half-billion dollars over time.

This week's sponsor is Bio-Rad.

After FDA U-turn, Amylyx eyes IPO to support ALS drug filings across the world

By Kyle LaHucik

Just like its approval request for a phase 2 ALS drug, Amylyx Pharmaceuticals is once again skirting convention and going forward with an initial public offering when the biotech market appears to be dipping.

Omega, backer of 150-plus biotechs, lands 7th and largest fund at $650M to build new companies

By Kyle LaHucik

With 150 biotechs to its name, Omega Funds closed its seventh and largest fund with $650 million to incubate drug developers, lead early financing rounds and back older startups on the brink of "cracking the problem."

Pfizer and Novartis' venture arms have joined investment firms in backing a $119 million series B for Anaveon. The Swiss biotech will deploy the proceeds on a phase 1/2 study in solid tumors.

Roche's Spark unit blueprints $575M gene therapy manufacturing center in Philly

By Annalee Armstrong

Roche’s Spark Therapeutics unit is pitching $575 million into a new gene therapy manufacturing facility at Drexel University’s Philadelphia campus that will work towards the next generation of genetic medicines.

Pfizer's peak COVID sales now pegged at $50B-plus, with vaccine still hauling in $25B by 2027: analysts

By Kevin Dunleavy

What do you get when you add the omicron variant to reduced effectiveness for Regeneron and Eli Lilly antibodies and a less-than-stellar report on Merck's ballyhooed antiviral? Mammoth sales for Pfizer's COVID-19 franchise, analysts say. Think $50 billion to $60 billion at peak—and a whopping $25 billion for the vaccine alone in 2027.

Precisely targeting liver cancer with logic-gated gene therapy

By Angus Liu

Borrowing a concept from computation, scientists at ETH Zurich created genetic “logic gates” that can differentiate between tumor and nontumor cells based on their molecular profiles. A gene therapy using the system significantly reduced tumor burden in mice with liver cancer while sparing healthy cells.

Allergan Aesthetics completes $550M Soliton buy following FTC probe

By Andrea Park

The deal folds Soliton’s flagship Resonic tattoo- and cellulite-removal device into the portfolio of AbbVie's medical aesthetics subsidiary.

Biogen vows to contest EMA rejection of Aduhelm as EU regulators question weak link to Alzheimer's clinical benefit

By Angus Liu

Biogen knew what was coming: After a drug review committee's negative “trend vote,” a rejection of Aduhelm from EU authorities seemed inevitable. So when the rebuff did come, the biotech pounced.

Oracle in talks to buy Cerner in potential $30B deal: WSJ

By Heather Landi

Oracle is in talks to buy healthcare IT giant Cerner, according to people familiar with the matter, a deal that could be worth around $30 billion, the Wall Street Journal reported.

Fierce Pharma Asia—Merck, Eisai's failed Lenvima trial; J&J, Legend's CAR-T data; AstraZeneca-Samsung COVID pact

By Angus Liu

Merck and Eisai's Lenvima failed a Keytruda combo trial in newly diagnosed lung cancer. Johnson & Johnson and Legend Biotech's CAR-T posted a long tail to disease progression. AstraZeneca and Samsung Biologics included AZ's COVID antibody in their contract manufacturing deal. And more.

Chutes & Ladders—Abbott's CEO and president is now also the medtech giant's chairman

By Kyle LaHucik

Abbott CEO and President Robert Ford becomes chair of the board as two-decade leader Miles White retires. Gritstone's chief medical officer leaves to helm the same post at Neogene Therapeutics. Former Iterum Therapeutics vice president returns as chief medical officer after brief stint away.

Biotech Innovators: How it Started

Podcast Series: Each month, discover an inspirational story of business leaders who are making a lasting impact in the life sciences and biotech space. Listen to the podcast.